Transition Agreements in the Pharmaceuticals Industry
73 Contracts & Agreements
- ACELRX PHARMACEUTICALS INC (1 contract)
- Adamis Pharmaceuticals Corp (1)
- Aerpio Pharmaceuticals, Inc. (2)
- ALDER BIOPHARMACEUTICALS INC (1)
- Altus Pharmaceuticals Inc. (1)
- Amphastar Pharma (1)
- APP Pharmaceuticals, Inc. (1)
- APRICUS BIOSCIENCES, INC. (2)
- Assertio Therapeutics, Inc (1)
- Astex Pharmaceuticals, Inc (1)
- Athira Pharma, Inc. (2)
- AUXILIUM PHARMACEUTICALS INC (1)
- AYTU BIOSCIENCE, INC (2)
- Baudax Bio, Inc. (1)
- BENTLEY PHARMACEUTICALS INC (1)
- Columbia Care Inc. (1)
- CPEX Pharmaceuticals, Inc. (1)
- Cure Pharmaceutical Holding Corp. (1)
- CymaBay Therapeutics, Inc. (1)
- Dova Pharmaceuticals Inc. (2)
- DUSA PHARMACEUTICALS INC (1)
- ENCYSIVE PHARMACEUTICALS INC (1)
- Evofem Biosciences, Inc. (1)
- Furiex Pharmaceuticals, Inc. (1)
- Haymaker Acquisition Corp. III (2)
- Horizon Pharma plc (1)
- Innoviva, Inc. (2)
- INSPIRE PHARMACEUTICALS INC (1)
- Jaguar Health, Inc. (1)
- Jazz Pharmaceuticals plc (3)
- KEMPHARM, INC (2)
- Lannett Company, Inc. (1)
- Lyra Therapeutics, Inc. (1)
- Mallinckrodt (1)
- MiddleBrook Pharmaceuticals, Inc. (1)
- Mylan N.V. (3)
- MyoKardia Inc (1)
- NEKTAR THERAPEUTICS (1)
- NPS PHARMACEUTICALS INC (1)
- Organon & Co. (2)
- Provention Bio, Inc. (1)
- Recro Pharma, Inc. (1)
- resTORbio, Inc. (2)
- SIGA TECHNOLOGIES INC (3)
- TETRALOGIC PHARMACEUTICALS CORP (1)
- Theravance Biopharma, Inc. (1)
- TITAN PHARMACEUTICALS INC (1)
- Upjohn Inc (3)
- Verrica Pharmaceuticals Inc. (1)
- Viamet Pharmaceuticals Holdings LLC (1)
- VIVUS INC (3)
- ZOGENIX, INC. (1)
- Zomedica Pharmaceuticals Corp. (1)
- Transition Agreement, effective January 11, 2024, by and between BioTe Medical, LLC and Samar Kamdar (Haymaker Acquisition Corp. III, Filed With SEC on March 15, 2024)
- Executive Transition Agreement dated January 5, 2024 (Athira Pharma, Inc., Filed With SEC on January 8, 2024)
- Amendment to the Amended and Restated Transition Agreement, dated January 1, 2024, between SIGA Technologies, Inc. and Phillip Louis Gomez, III (SIGA TECHNOLOGIES INC, Filed With SEC on January 2, 2024)
- Transition and Release of Claims Agreement, between Columbia Care Inc. and Rosemary Mazanet, dated August 31, 2023 (Columbia Care Inc., Filed With SEC on November 14, 2023)
- Transition Service Agreement by and between Amphastar Pharmaceuticals, Inc., and Eli Lilly and Company, dated June 30, 2023 (Amphastar Pharma, Filed With SEC on August 9, 2023)
- Transition and Advisory Agreement and Release, dated May 19, 2023, by and between Viatris Inc. and Robert J. Coury (Upjohn Inc, Filed With SEC on August 7, 2023)
- Amended and Restated Transition Agreement, dated July 26, 2023, between SIGA Technologies, Inc. and Phillip Louis Gomez, III (SIGA TECHNOLOGIES INC, Filed With SEC on July 28, 2023)
- Transition Services Agreement between the Company and Glenna Mileson, dated as of May 18, 2023 (Athira Pharma, Inc., Filed With SEC on May 22, 2023)
- Transition Agreement, dated as of May 6, 2023, between Zevra Therapeutics, Inc. and Richard W. Pascoe (KEMPHARM, INC, Filed With SEC on May 8, 2023)
- Notice of Resignation and Transition Agreement, effective February 20, 2023, between CymaBay Therapeutics, Inc. and Dennis Kim (CymaBay Therapeutics, Inc., Filed With SEC on February 23, 2023)
- Transition and Support Agreement by and among Qorvo Biotechnologies, LLC, Zomedica Inc. and Zomedica Corp (Zomedica Pharmaceuticals Corp., Filed With SEC on January 24, 2023)
- Transition Agreement, dated January 13, 2023, between SIGA Technologies, Inc. and Phillip Louis Gomez, III (SIGA TECHNOLOGIES INC, Filed With SEC on January 17, 2023)
- Transition Agreement, dated as of January 4, 2023, as amended, between KemPharm, Inc. and Travis C. Mickle, Ph.D (KEMPHARM, INC, Filed With SEC on January 9, 2023)
- Transition agreement, effective August 31, 2022, by and between BioTE Medical, LLC and Robbin Gibbins (Haymaker Acquisition Corp. III, Filed With SEC on November 14, 2022)
- Executive Employment and Transition Agreement, dated May 11, 2022, by and among Horizon Therapeutics Public Limited Company, Horizon Therapeutics USA, Inc. and Paul W. Hoelscher (Horizon Pharma plc, Filed With SEC on August 3, 2022)
- Transition Services Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer (Cure Pharmaceutical Holding Corp., Filed With SEC on July 28, 2022)
- Transition Agreement, dated November 1, 2021, between Provention and Andrew Drechsler (Provention Bio, Inc., Filed With SEC on February 24, 2022)
- Confidential Employment Transition Plan and General Release Agreement, dated November 12, 2021 (Evofem Biosciences, Inc., Filed With SEC on November 15, 2021)
- Transition Agreement between the Registrant and R. Don Elsey dated as of September 12, 2021 (Lyra Therapeutics, Inc., Filed With SEC on November 9, 2021)
- Transition Services Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co (Organon & Co., Filed With SEC on June 3, 2021)
- Transition Services Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co (Organon & Co., Filed With SEC on June 3, 2021)
- Termination and Transition Agreement between Aytu BioPharma, Inc. and Acerus Pharmaceuticals Corporation, dated March 31, 2021 (AYTU BIOSCIENCE, INC, Filed With SEC on May 17, 2021)
- Amendment to Transition Services Agreement, entered into on April 1, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin G. Peters (Aerpio Pharmaceuticals, Inc., Filed With SEC on April 1, 2021)
- Transition Services Agreement, entered into on February 9, 2021, by and between Aerpio Pharmaceuticals, Inc. and Kevin Peters (Aerpio Pharmaceuticals, Inc., Filed With SEC on February 16, 2021)
- Transition Services Agreement, dated as of November 16, 2020, by and between Upjohn Inc. (as Service Provider) and Pfizer Inc. (as Service Recipient) (Upjohn Inc, Filed With SEC on November 19, 2020)
- Transition Services Agreement, dated as of November 16, 2020, by and between Pfizer Inc. (as Service Provider) and Upjohn Inc. (as Service Recipient) (Upjohn Inc, Filed With SEC on November 19, 2020)
- Transition Agreement, dated April 28, 2020, as amended, by and between Adicet Therapeutics, Inc. and Anil Singhal (resTORbio, Inc., Filed With SEC on September 16, 2020)
- *** Certain identified information hasbeen omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrantif publicly... (Adamis Pharmaceuticals Corp, Filed With SEC on August 17, 2020)
- Transition Agreement, dated April 28, 2020, as amended, by and between Adicet Bio, Inc. and Anil Singhal (resTORbio, Inc., Filed With SEC on June 23, 2020)
- Transition Agreement between Innoviva, Inc. and Geoffrey L. Hulme, dated June 11, 2020 (Innoviva, Inc., Filed With SEC on June 12, 2020)
- Amendment to Transition and Termination Agreement, dated as of March 31, 2020, by and between Jazz Pharmaceuticals, Inc. and Michael Miller (Jazz Pharmaceuticals plc, Filed With SEC on May 5, 2020)
- Transition Services Agreement and General Release (ACELRX PHARMACEUTICALS INC, Filed With SEC on April 8, 2020)
- Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins, dated as of March 16, 2020 (Assertio Therapeutics, Inc, Filed With SEC on March 17, 2020)
- Transition Services Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Baudax Bio, Inc., Filed With SEC on November 26, 2019)
- Transition Services Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Recro Pharma, Inc., Filed With SEC on November 26, 2019)
- Transition and Termination Agreement, dated as of November 2, 2019, by and between Jazz Pharmaceuticals, Inc. and Mike Miller (Jazz Pharmaceuticals plc, Filed With SEC on November 5, 2019)
- Transition Agreement, by and between the Registrant and June Lee dated October 4, 2019 (MyoKardia Inc, Filed With SEC on November 4, 2019)
- Transition Services Agreement, dated November 1, 2019 (AYTU BIOSCIENCE, INC, Filed With SEC on November 4, 2019)
- Transition Employment Letter Agreement, dated as of February 6, 2019, by and between Jazz Pharmaceuticals, Inc. and Suzanne Sawochka Hooper (Jazz Pharmaceuticals plc, Filed With SEC on May 7, 2019)
- Transition Agreement between Alder BioPharmaceuticals, Inc. and Elisabeth A. Sandoval, dated November 2, 2018 (ALDER BIOPHARMACEUTICALS INC, Filed With SEC on February 25, 2019)
